Skip to content

Lymph Node Metastasis in Early Esophageal Squamous Cell Carcinoma

Deep Learning and Radiomics for Prediction of Lymph Node Metastasis in Early-stage Esophageal Squamous Cell Carcinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07050576
Enrollment
500
Registered
2025-07-03
Start date
2024-05-01
Completion date
2025-11-30
Last updated
2025-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ESCC, Lymph Node Metastasis, Radiomics

Keywords

ESCC, Lymph node metastasis, radiomics

Brief summary

This study aims to develop a predictive model using deep learning and radiomics to assess the likelihood of lymph node metastasis in patients with early-stage esophageal squamous cell carcinoma (ESCC). Lymph node metastasis is a critical factor in determining the treatment approach and prognosis for ESCC patients. By analyzing medical imaging data, we hope to create a non-invasive method that can assist doctors in making more accurate treatment decisions. This research could improve patient outcomes by enabling earlier and more tailored interventions.

Interventions

DIAGNOSTIC_TESTThe prediction model of lymph node metastasis in early esophageal squamous cell carcinoma

The predictive performance of the model was validated in the test set. The optimal prediction model was determined based on the AUC and ACC. To assess the robustness of the chosen model, ROC analysis was conducted on the external validation set.

Sponsors

The First Affiliated Hospital of Anhui Medical University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients with pathologically confirmed early-stage (T1) ESCC * Preoperative contrast-enhanced CT data within 2 weeks before surgery * Without any treatment before surgical resection

Exclusion criteria

* Patients who underwent neoadjuvant therapy or endoscopic treatment * Insufficient CT imaging or poor CT quality * Incomplete pathology results * Presence of metastatic disease

Design outcomes

Primary

MeasureTime frameDescription
AUC(the area under the curve) values of the model4 yearsThe performance and clinical relevance of the models were assessed by analyzing the area under the curve (AUC).

Countries

China

Contacts

Primary ContactHao Zheng, MD
pojunayfy@gmail.com+86 139 1793 6873

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026